Advertisement
Advertisement
November 16, 2026
Sirtex Acquires FDA-Cleared Hourglass Vascular Plug
KEY TAKEAWAYS
- Sirtex Medical has acquired the Hourglass vascular plug, expanding its embolization device portfolio.
- The FDA-cleared device is indicated for reducing or obstructing blood flow in peripheral vessels measuring 6 to 8 mm in diameter.
- Sirtex is preparing to make Hourglass available to physicians after a previous limited market release in the United States.
November 16, 2026—Sirtex Medical, a developer of interventional oncology and embolization solutions, announced it has acquired the Hourglass embolization plug. The device joins Sirtex’s embolization portfolio alongside the Lava liquid embolic system, stated the company.
According to Sirtex, Hourglass is an FDA-cleared vascular plug indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature in vessels 6 to 8 mm in diameter. It initially received FDA 510(k) clearance in 2017.
Hourglass was previously introduced in the United States through a limited market release. Sirtex is completing the work needed to make the device available to physicians and will share availability details with customers, noted the press release.
“Dependable occlusion tools are central to treating a growing range of conditions with embolization,” commented Gary Siskin, MD, who is Professor and Chair of Radiology at Albany Medical Center in Albany, New York, in the press release. “My experience with Hourglass was very positive, and I look forward to this device being available to physicians and their patients.”
Advertisement
Advertisement